Poor glycemic control is considered harmful in people with diabetes and chronic kidney disease; however, the ideal hemoglobin A1c target continues to be elusive. What can we learn from new observational evidence published by Shurraw et al. in the Archives of Internal Medicine?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hydrogen sulfide ameliorates chronic renal failure in rats by inhibiting apoptosis and inflammation through ROS/MAPK and NF-κB signaling pathways
Scientific Reports Open Access 28 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).
Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).
Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412 (2000).
Khaw, K. T. et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141, 413–420 (2004).
Zoungas, S. et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410–1418 (2010).
Shurraw, S. et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch. Intern. Med. 171, 1920–1927 (2011).
Currie, C. J. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375, 481–489 (2010).
Riddle, M. C. et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33, 983–990 (2010).
Zoungas, S. et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia http://dx.doi.org/10.1007/s00125-011-2404–1.
Acknowledgements
S. Zoungas is supported by a Heart Foundation of Australia Career Development Award.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Sophia Zoungas has received speaker honoria from Servier, MSD, Novartis, Novo Nordisk, Boehringer Ingelheim, Sanofi Aventis, AstraZeneca and Bristol-Myers Squibb, and served on external advisory boards for MSD, Novo Nordisk, Sanofi Aventis and Boehringer Ingelheim.
John Chalmers holds a research grant from Servier as principal investigator for ADVANCE and ADVANCE-ON. J Chalmers has received lecturing fees and served on external advisory boards for Servier.
Rights and permissions
About this article
Cite this article
Zoungas, S., Chalmers, J. Glycemic control and outcomes in people with diabetes and CKD. Nat Rev Nephrol 8, 133–134 (2012). https://doi.org/10.1038/nrneph.2012.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.18
